<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ACICLOVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ACICLOVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#professionSpecificInformation" data-toggle="tab">Profession specific information</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex infection (local treatment)</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 5 times a day for 5&#8211;10 days, to be applied to lesions every 4 hours, starting at first sign of attack.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 5 times a day for 5&#8211;10 days, to be applied to lesions every 4 hours, starting at first sign of attack.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, suppression</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6&#8211;12 months to reassess recurrence frequency&#8212;consider restarting after two or more recurrences.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6&#8211;12 months to reassess recurrence frequency&#8212;consider restarting after two or more recurrences.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, prophylaxis in the immunocompromised</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;400 mg 4 times a day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg/kg every 8 hours.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                100&#8211;200 mg 4 times a day.</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                200&#8211;400 mg 4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, treatment (non-genital)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                100 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes simplex, treatment (non-genital) in simplex encephalitis, immunocompromised patients or if absorption impaired</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes simplex, treatment of first episode</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg 5 times a day, alternatively 400 mg 3 times a day both courses usually for 5 days (longer if new lesions appear during treatment or if healing incomplete).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes simplex, treatment of severe, initial infection</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg/kg every 8 hours usually for 5 days; increased to 10 mg/kg every 8 hours for at least 14 days in encephalitis (at least 21 days if also immunocompromised)&#8212;confirm cerebrospinal fluid negative for herpes simplex virus before stop- ping treatment, to be increased only if resistant organisms suspected or in simplex encephalitis.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes simplex, treatment of first episode in immunocompromised or HIV-positive patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg 5 times a day for 7&#8211;10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes simplex, treatment of recurrent infection</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg 3 times a day for 2 days, alternatively 200 mg 5 times a day for 5 days, alternatively 400 mg 3 times a day for 3&#8211;5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Genital herpes simplex, treatment of recurrent infection in immunocompromised or HIV-positive patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg 3 times a day for 5&#8211;10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Varicella zoster (chickenpox), treatment</span>,
                <span class="indication">Herpes zoster, treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg 5 times a day for 7 days.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg/kg every 8 hours usually for 5 days.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                200 mg 4 times a day for 5 days.</li>
              <li class="dose child"><strong>For children 2&#8211;5 years</strong><br/>
                400 mg 4 times a day for 5 days.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                800 mg 4 times a day for 5 days.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                800 mg 5 times a day for 7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Herpes zoster, treatment in immunocompromised</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg 5 times a day continue for 2 days after crusting of lesions.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg/kg every 8 hours given for 10&#8211;14 days in encephalitis, possibly longer if also immunocompromised.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                200 mg 4 times a day continue for 2 days after crusting of lesions.</li>
              <li class="dose child"><strong>For children 2&#8211;5 years</strong><br/>
                400 mg 4 times a day continue for 2 days after crusting of lesions.</li>
              <li class="dose child"><strong>For children 6&#8211;12 years</strong><br/>
                800 mg 4 times a day continue for 2 days after crusting of lesions.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                800 mg 5 times a day continue for 2 days after crusting of lesions.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Varicella zoster (chickenpox) attenuation of infection if varicella&#8211;zoster immunoglobulin not indicated</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg/kg 4 times a day for 7 days, to be started 1 week after exposure.</li>
              <li class="dose child"><strong>For children </strong><br/>
                10 mg/kg 4 times a day for 7 days, to be started 1 week after exposure.</li>
            </ul>
          </section>
        </section>
        
        
        
            <section class="extremesOfBodyWeight">
                <h3>Doses at extremes of body-weight</h3>
              <p>To avoid excessive dosage in obese patients parenteral dose should be calculated on the basis of ideal weight for height.</p>
            </section>
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Not known to be harmful&#8212;manufacturers advise use only when potential benefit outweighs risk.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Limited absorption from topical aciclovir preparations.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>Use normal intravenous dose every 12 hours if eGFR 25&#8211;50&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup> (every 24 hours if eGFR 10&#8211;25 mL/minute/ 1.73&#8239;m<sup>2</sup>). </p><p>Consult product literature for intravenous dose if eGFR less than 10&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>For <i>herpes zoster</i>, use normal oral dose every 8 hours if eGFR 10&#8211;25&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (every 12 hours if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>).</p><p>For <i>herpes simplex</i>, use normal oral dose every 12 hours if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>Use <i>normal intravenous dose</i> every 12 hours if estimated glomerular filtration rate 25&#8211;50&#8239;mL/minute/1.73m<sup>2</sup> (every 24 hours if estimated glomerular filtration rate 10&#8211;25&#8239;mL/minute/1.73m<sup>2</sup>.</p><p>Consult product literature for intravenous dose if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>For <i>herpes zoster</i>, use normal oral dose every 8 hours if estimated glomerular filtration rate 10&#8211;25&#8239;mL/minute/1.73m<sup>2</sup> (every 12 hours if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73m<sup>2</sup>.</p><p>For <i>herpes simplex</i>, use normal dose every 12 hours if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Risk of neurological reactions increased.</p><p>Maintain adequate hydration (especially during renal impairment).</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> local inflammation, local irritation, superficial punctate keratopathy, abdominal pain, diarrhoea, fatigue, headache, nausea, photosensitivity, pruritus, rash, urticaria, vomiting,
              </p>
              <p>
                <strong>rare:</strong> blepharitis,
              </p>
              <p>
                <strong>veryRare:</strong> angioedema, hypersensitivity reactions, agitation, fever, psychosis, severe local inflammation (sometimes leading to ulceration), tremors, acute renal failure, anaemia, ataxia, confusion, convulsions, dizziness, drowsiness, dysarthria, dyspnoea, hallucinations, hepatitis, jaundice, leucopenia, neurological reactions, thrombocytopenia,
              </p>
              <p>
                <strong>notKnown:</strong> drying of the skin, erythema, itching of the skin, transient burning, transient stinging,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, reconstitute to 25&#8239;mg/mL with Water for Injections or Sodium Chloride 0.9% then dilute to concentration of 5&#8239;mg/mL with Sodium Chloride 0.9% or Sodium Chloride and Glucose and give over 1 hour; alternatively, may be administered in a concentration of 25&#8239;mg/mL using a suitable infusion pump and central venous access and given over 1 hour.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i>
            <i>Zovirax IV</i>
            <tm tmtype="reg"/>, <i>Aciclovir IV</i>(Genus), give intermittently <i>in</i> Sodium chloride 0.9% <i>or</i> Sodium chloride and glucose; initially reconstitute to 25&#8239;mg/mL in water for injection or sodium chloride 0.9% then dilute to not more than 5&#8239;mg/mL with the infusion fluid; to be given over 1 hour; alternatively, may be administered in a concentration of 25&#8239;mg/mL using a suitable infusion pump and given over 1 hour; for <i>Aciclovir IV </i>(Hospira) dilute to not more than 5&#8239;mg/mL with infusion fluid; give over 1 hour.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Aciclovir (oral) for viral infections</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/aciclovir-for-viral-infections">www.medicinesforchildren.org.uk/aciclovir-for-viral-infections</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Aciclovir cream for herpes</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/aciclovir-cream-for-herpes">www.medicinesforchildren.org.uk/aciclovir-cream-for-herpes</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Aciclovir eye ointment for herpes simplex infections</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/aciclovir-eye-ointment-for-herpes-simplex-infection">www.medicinesforchildren.org.uk/aciclovir-eye-ointment-for-herpes-simplex-infection</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With systemic use:</strong>
            elderly (risk of neurological reactions) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            maintain adequate hydration (especially with infusion or high doses)
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid cream coming in to contact with eyes and mucous membranes
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in children</h3>
              <p>Cream licensed for use in children (age range not specified by manufacturer).</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Tablets and suspension not licensed for attenuation of chickenpox (if varicella-zoster immunoglobulin not indicated) in children under 18 years.</p><p>Tablets and suspension not licensed for suppression of herpes simplex or for treatment of herpes zoster in children (age range not specified by manufacturer).</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Intravenous infusion not licensed for herpes zoster in children under 18 years.</p>
            </section>
            <section class="unlicensedUse">
              <p>Aciclovir doses in BNF may differ from those in product literature (systemic use).</p><p>Attenuation of chickenpox is an unlicensed indication.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid preparations may include banana, or orange.</p>
            </section>
      </section>






      <section class="tab-pane" id="professionSpecificInformation">
        <h2>Profession specific information</h2>

          <h3>Dental practitioners</h3>
        
            <section class="dentalPractitionersFormulary">
              <p>Aciclovir Tablets 200&#8239;mg or 800&#8239;mg may be prescribed.</p><p>Aciclovir Oral Suspension 200&#8239;mg/5mL may be prescribed.</p><p>Aciclovir Cream may be prescribed.</p>
            </section>
      </section>

      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>A 2-g tube and a pump pack are on sale to the public for the treatment of cold sores.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ACICLOVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76798"><a href="../medicinalForm/PHP76798.html" data-target="#PHP76798" data-action="load">Tablet</a></div>
            <div id="PHP76811"><a href="../medicinalForm/PHP76811.html" data-target="#PHP76811" data-action="load">Dispersible tablet</a></div>
            <div id="PHP76820"><a href="../medicinalForm/PHP76820.html" data-target="#PHP76820" data-action="load">Oral suspension</a></div>
            <div id="PHP76830"><a href="../medicinalForm/PHP76830.html" data-target="#PHP76830" data-action="load">Solution for infusion</a></div>
            <div id="PHP76824"><a href="../medicinalForm/PHP76824.html" data-target="#PHP76824" data-action="load">Powder for solution for infusion</a></div>
            <div id="PHP76792"><a href="../medicinalForm/PHP76792.html" data-target="#PHP76792" data-action="load">Eye ointment</a></div>
            <div id="PHP76805"><a href="../medicinalForm/PHP76805.html" data-target="#PHP76805" data-action="load">Cream</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
